Schrödinger's 12% Start Meets BMS's Bunsen Rollout: Real 2026 Growth or Hype Trap?

A 12% first quarter makes Schrödinger's 2026 target easier to take seriously

Schrödinger's 12% first-quarter ACV growth moves Bunsen closer to a real commercial conversation. Last week's strategic agreement with Bristol Myers Squibb to deploy Bunsen matters because BMS is not a one-off tester. It is a long-standing customer and collaborator, and the deal significantly expands the application of Schrödinger's platform.

Why the 10%-15% guide looks more credible

Earlier this month, Schrödinger said first quarter ACV was $28.4 million and said 12% ACV growth was driven by usage scale-ups and new deployments. Management also maintained its 2026 ACV growth guide of 10% to 15%. With actual usage expansion and a named pharma deployment visible at the same time, the target looks more attainable than purely narrative-driven.

The bull case is straightforward: if BMS is an early signal of broader enterprise adoption, the 10% to 15% range is a reasonable bar. The bear case is just as clear: one strategic deployment does not yet prove a repeatable sales pattern. For now, investors are judging whether BMS is the start of a trend or simply a strong first data point.

Bunsen's value is in workflow depth, not just AI branding

How Bunsen could expand usage inside existing customers

Bunsen is not a generic chatbot layered on top of the product. It is built to plan computational strategies, execute sophisticated discovery workflows, and interpret results using Schrödinger's validated, physics-based computational platform. Management has also said Bunsen is meant to lower the barrier for non-expert users to deploy sophisticated technology.

That is the core mechanism bulls are watching. If more scientists can run complex workflows without relying on a small center of excellence, each platform deployment can do more work inside the same organization. More workflows, more runs, and broader daily use can support the usage scale-ups Schrödinger has already reported.

That pattern is already partly visible. Schrödinger said recent growth was driven by usage scale-ups and new deployments, and management also highlighted usage scale-ups among top 20 pharma customers. Bunsen matters because it could help turn those expansions into a broader usage model rather than isolated wins.

Why the BMS deal matters beyond the headline

The BMS announcement is notable not only because Bunsen is being deployed, but also because Schrödinger said it will work with BMS on additional Bunsen functionality alongside its computational technologies and RetroSynth. The agreement is designed to help BMS scientists prioritize molecules with greater confidence and accelerate discovery decisions. In practical terms, Schrödinger is reaching deeper into the discovery routine rather than offering only a smarter interface.

That kind of integration can improve revenue stickiness. Once software helps shape which molecules move forward, how synthesis plans are built, and how results are interpreted, the spend can become harder to treat as optional. Even so, this is still early evidence rather than proof of monetization.

The hosted transition matters for how usage turns into revenue

Schrödinger is moving from on-premise toward hosted licensing, with a goal of 75% hosted software mix within a three-year period. That matters because hosted and throughput-based models can track actual usage more closely than static installations. If Bunsen increases activity on the platform, the licensing shift can help capture more of that usage in revenue.

One important boundary condition: this is still a wallet-share story, not an immediate profitability shortcut. Investors should keep the hosted transition in mind when evaluating both revenue quality and margins.

What to watch next

• Whether usage scale-ups among top 20 pharma customers continue beyond the first quarter
• Whether hosted and throughput-based licensing rise as Bunsen usage rises
• Whether the platform's ground truth simulations continue to be highlighted as adoption broadens